Citations

Clear

360 citation(s) found for "Simmons, D".

Immune stromal components impede biological effectiveness of carbon ion therapy in a preclinical model of pancreatic ductal adenocarcinoma
Swancutt, Katy L. , Nicholson, James H., Alves, Elizabeth M. , Hamilton, Cassandra , Rusek, A., Davis, Anthony J. , Story, Michael D. , Aguilera, Todd A. , Elghonaimy, Eslam A , Pop, Laurentiu M , Sishc, Brock J. , Alves, Elizabeth M , Hamilton, Cassandra , Davis, Anthony J , Hannan, Raquibul , Aguilera, Todd A , Pop, Laurentiu M.

Mayo Clinic

No container title available | May 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.17.654632 | PMID 40475579 Get It

Abstract The tumor landscape of pancreatic ductal adenocarcinoma (PDAC) is refractory to conventional photon radiotherapy (RT) due to a fibrotic tumor microenvironment (TME) that promotes chronic hypoxia and reduced immune surveillance. The radiobiological factors unique to carbon ion radiotherapy (CIRT), such as high linear energy transfer (LET) and less dependence on oxygen, make it well-suited to overcome the PDAC TME. Here, we utilized clonal syngeneic KPC pancreatic tumor cell lines and tumors to examine this postulate and to identify underlying factors that impact the response of PDAC to CIRT. While KPC cell lines exhibited radiobiologic effectiveness (RBE) greater than 3, subcutaneous tumors in the mouse hind leg showed lower RBEs – 1.3 based on quintupling time – at a LET of 75 keV/μm. Four days after CIRT, we observed widespread transcriptomic changes in the tumor immune microenvironment (TME), suggesting increased infiltration of anti-tumor immune cells, elevated expression of anti-tumor T cell cytokines, MHC class I molecules, and co-stimulatory signals. Fewer immunologic changes were observed following photon irradiation. By seven days after CIRT, tumor-supportive transcriptomic programs characterized by pro-tumor cytokines, M2 macrophages, and cancer-associated fibroblasts (CAFs) emerged, promoting resistance and limiting the durability of tumor growth delay. These findings suggest that CIRT may offer a favorable platform compared to conventional photon radiation therapy for combining with immunotherapies. Furthermore, these data highlight the risk of using in vitro survival data alone in treatment planning and indicate that underlying TME factors impact the response of PDAC in vivo .
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry , Costello, Caitlin , D’Angelo, Christopher R. , Derman, Benjamin A. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Robinson, Timothy, Valent, Jason , Varshavsky‐Yanovsky, Asya, Kovách, E, Holmberg, Leona , Anderson, Larry D. , Anderson, Larry D , Derman, Benjamin A , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Devarakonda, Srinivas , Kang, Yubin , Lee, Hans C. , Martin, Thomas G. , Rosenberg, Aaron , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovach, Emily, Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 132-140

10.6004/jnccn.2025.0023 | PMID 40340857 Get It

The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Buse, John B. , Kahn, Steven E. , Aroda, Vanita R. , Auchus, Richard J. , Busch, Robert S. , Christofides, Elena A. , DeFronzo, Ralph A. , Eilerman, Bradley , Findling, James W. , Handelsman, Yehuda , Miller, Harold J., Ownby, Jonathan G., Parker, John C. , Philis‐Tsimikas, Athena , Rosenstock, Julio , Shanik, Michael H., Sloan, Lance L., Tudor, Iulia Cristina , Schlafly, Tina K. , Einhorn, Daniel , Investigators*, CATALYST, Kruszon, Lauren, Fruiterman, Abbey, Handelsman, Yehuda, Heidarpour, Narges, Ownby, Jonathan G., Stephens, Nashia, Aroda, Vanita R., Gyurko, Rita, Rao, Pratibha, Paulus, Kelly, Kipnes, Mark, Ryan, Terri, Shanik, Michael H., Iannuzzi, Lisa, Umpierrez, Guillermo, Centeno, Gloria, Eskeland, Andrew, Swerdloff, Ronald S., Ruiz, Elizabeth, Park, Jean, Hurtado, Maria, Ghazi, Adline , Hamm, M., Ducote, Rosina, Blonde, Lawrence , Williams, Shannon, Wyne, Kathleen , Aldrich, Lindsey, Ahmann, Andrew , Branigan, Deborah , Nakhle, Samer, Sandry, Sasha, Rosal, Rosario, Hardy, Cashmere, Sloan, Lance , Sloan, Kátia Portero , Lerman, Sam, Simmons, Mary, Auchus, Richard J., Varela, Tamara Blanco, Gassaway, Franziska, DeFronzo, Ralph A., Puckett, Curtiss, Atkinson, Karen, Zimmerman, Michael, Jacobsen, Colleen, Wenker, Matthew, Schultz, Austin, Lender, Dan, Camacho, Allison, Leibowitz, Mark D., Sánchez, Rosario, Delgado, John , Jaasko, Kari, Hsia, Stanley H. , Rodríguez, Cecilia, Guzman, David , Garibay, Lourdes, Chang, Margaret, Nixon, Tatyana, Christofides, Elena A , DeFronzo, Ralph A , Eilerman, Bradley , Fonseca, Vivian , Handelsman, Yehuda , Rosenstock, Julio , Umpierrez, Guillermo E. , Schlafly, Tina K , Philis-Tsimikas, Athena , Kahn, Steven , Buse, John B , Bailey, Timothy S. , Bancos, Irina , Fonseca, Vivian , Hamidi, Oksana , Pratley, Richard E. , Sloan, Lance L., Investigators*, CATALYST, Handelsman, Yehuda, Ownby, Jonathan G., Aroda, Vanita R., Shanik, Michael H., Umpierrez, Guillermo, Centeno, Gloria, Ruiz, Elizabeth, Aldrich, Lindsey, Botte, Jennifer, Hardy, Cashmere, Martin, Maria Jesus , Lovre, Dragana , Simmons, Mary, Auchus, Richard J., Pop‐Busui, Rodica , DeFronzo, Ralph A., Zimmerman, Michael, Wenker, Matthew, Schultz, Austin, Chang, Margaret, Nixon, Tatyana

Mayo Clinic

Diabetes Care | May 7, 2025 | Volume: 48 | Issue: 12 | Pages: 2012-2020

10.2337/dc24-2841 | PMID 40249765 Get It

OBJECTIVE Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control. RESEARCH DESIGN AND METHODS Individuals with type 2 diabetes and HbA1c 7.5%–11.5% (58–102 mmol/mol) on two or more glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure–lowering medications were screened with a 1-mg dexamethasone suppression test. Common causes of false-positive DSTs were excluded. The primary end point was the prevalence of hypercortisolism, defined as post-DST cortisol >1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed with multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed. RESULTS Post-DST cortisol was unsuppressed in 252 of 1,057 participants (prevalence 23.8%; 95% CI 21.3, 26.5). Hypercortisolism prevalence was 33.3% among participants with cardiac disorders and 36.6% among those taking three or more blood pressure–lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of sodium–glucose cotransporter 2 inhibitors (odds ratio 1.558), maximum-dose glucagon-like peptide 1 receptor agonists (1.544), tirzepatide (1.981), or a higher number of blood pressure–lowering medications (1.390); older age (1.316); BMI <30 kg/m2 (1.639); non-Latino/Hispanic ethnicity (3.718); and use of fibrates (2.676) or analgesics (1.457) were associated with higher prevalence (all P < 0.03). CONCLUSIONS Hypercortisolism was associated with hyperglycemia in approximately one-quarter of individuals with inadequately controlled type 2 diabetes despite multiple medications.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
Garje, Rohan , Riaz, Irbaz Bin , Naqvi, Syed Arsalan Ahmed , Rumble, R. Bryan , Taplin, Mary‐Ellen , Kungel, Terry M. , Herchenhorn, Daniel , Zhang, Tian , Beckermann, Kathryn E. , Vapiwala, Neha , Celano, Paul , Hotte, Sebastién J. , Borno, Hala T. , Bryce, Alan H. , Wulff‐Burchfield, Elizabeth , He, Huan, Williams, J.E. Caerwyn , Hotte, Sebastien J , Basu, Arnab , Borno, Hala , Bryce, Alan H , Wulff-Burchfield, Elizabeth , Bodei, Lisa , Hamilton, Robert J , Emamekhoo, Hamid , Hope, Thomas A , Murad, M Hassan , Liu, Hongfang , Williams, James E , Parikh, Rahul A , Garje, Rohan , Herchenhorn, Daniel , He, Huan , Riaz, Irbaz B , Beckermann, Katy , Rumble, R Bryan , Carducci, Michael A. , Basu, Arnab , Wang, Peng , Bodei, Lisa , Loblaw, Andrew , Emamekhoo, Hamid , Hope, Thomas A. , Murad, M. Hassan , Liu, Hongfang

Mayo Clinic

Journal of Clinical Oncology | May 2, 2025 | Volume: 43 | Issue: 20 | Pages: 2311-2334

10.1200/jco-25-00007 | PMID 40315400 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic agents (docetaxel, cabazitaxel), radiopharmaceuticals (radium 223, 177 Lu-prostate-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS) benefit for patients with mCRPC. For patients with BRCA1 / 2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olaparib and/or niraparib + abiraterone) has shown clinical benefit. For patients with BRCA1 / 2 alterations who received prior ARPI or ARPI followed by docetaxel, olaparib showed OS benefit. In select patients with microsatellite instability-high/mismatch repair-deficient, pembrolizumab showed clinical efficacy. RECOMMENDATIONS Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early adoption of somatic genetic testing and palliative care is recommended. Patients with mCRPC and bony metastases should receive a bone-protective agent. The panel recommends the combination of ARPI with PARPi in patients with BRCA1 / 2 alterations who did not receive prior ARPI. For patients who received prior ARPI, the panel recommends docetaxel chemotherapy. The panel recommends 177 Lu-PSMA-617 or cabazitaxel chemotherapy for patients who receive prior ARPI and docetaxel chemotherapy. For patients with BRCA1 / 2 alterations who received prior ARPI, the panel recommends PARPi monotherapy. Radium 223 is recommended for patients with symptomatic bone–only disease. Evidence for optimal sequencing for mCRPC regimens is lacking. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .
Autologous Transplant or CAR‐T as Consolidation Options in MYC Rearranged Large B‐Cell Lymphoma Patients in Remission After Salvage Treatments
Furqan, Fateeha , Ahn, Kwang Woo , Kaur, Manmeet , Patel, Jinalben , Ansell, Stephen M. , Awan, Farrukh T. , Baird, John H. , Farooq, Umar , Fung, Henry C., Khurana, Arushi , Lekakis, Lazaros J. , Lutfi, Forat , McCarty, John M. , Mukherjee, Akash , Nath, Rajneesh , Winter, Allison , Sauter, Craig S. , Herrera, Alex F. , Smith, Melody , Ansell, Stephen M , Baird, John , Khurana, Arushi , Winter, Allison , Shadman, Mazyar , Herrera, Alex F , Awan, Farrukh T , Smith, Melody , Bezerra, Evandro D. , Farooq, Umar, Romancik, Jason T. , Schuster, Stephen J. , Smith, Melody , Turtle, Cameron J. , Shadman, Mazyar , Hamadani, Mehdi

Mayo Clinic

American Journal of Hematology | April 15, 2025 | Volume: 100 | Issue: 7 | Pages: 1152-1162

10.1002/ajh.27687 | PMID 40231369 Get It

ABSTRACTAlthough recent studies have demonstrated the efficacy of chimeric antigen receptor T‐cell (CAR‐T) therapy in relapsed large B‐cell lymphoma (LBCL) with MYC rearrangement (R‐MYC), the data comparing CAR‐T to autologous hematopoietic cell transplant (auto‐HCT) in such patients who achieve a complete or partial response (CR/PR) after salvage therapies are limited. We compared the clinical outcomes of patients with R‐MYC LBCL (including double and triple hit lymphomas) who underwent CAR‐T or auto‐HCT after achieving a CR/PR with salvage therapies using the Center for International Blood & Marrow Transplant Research registry. Among the 252 patients (auto‐HCT = 98, CAR‐T = 154), relative to auto‐HCT, CAR‐T was associated with significantly lower overall survival (OS) (Hazard Ratio [HR] 2.09, 95% CI 1.38–3.15, p < 0.001) on multivariate analysis. There were no differences in progression‐free survival (PFS) (HR 1.21, 95% CI 0.81–1.8 p = 0.36), risk of relapse (HR 1.1, 95% CI 0.71–1.69 p = 0.68), nonrelapse mortality (NRM) (HR 1.74, 95% CI 0.64–4.7 p = 0.28) while the post‐relapse survival was longer in auto‐HCT relative to CAR‐T (HR 1.93, 95% CI 1.21–3.06 p = 0.01). On propensity score matched analysis accounting for differences in characteristics across the two cohorts, we detected no significant differences in OS (HR 1.72, 95% CI 0.92–3.21 p = 0.09), PFS (HR 1.04, 95% CI 0.64–1.68 p = 0.88), NRM (HR 1.22, 95% CI 0.35–4.2 p = 0.76), relapse (HR = 0.93, 95% CI 0.54–1.6 p = 0.8) and post‐relapse survival (HR 2.25, 95% CI 0.98–5.17, p = 0.06). These data, although retrospective, support consideration for auto‐HCT in patients with R‐MYC LBCL who achieve a CR/PR after salvage therapies, particularly in regions with no or limited access to CAR‐T.
GLIM consensus approach to diagnosis of malnutrition: A 5‐year update
Jensen, Gordon L. , Cederholm, Tommy , Correia, María Isabel Toulson Davisson , González, Marı́a Cristina , Fukushima, Ryoji , Pisprasert, Veeradej , Cárdenas, Diana , Carrasco, Fernando , Cruz‐Jentoft, Alfonso J. , Cuerda, Cristina , Evans, David C. , Hasse, Jeanette M. , Hiki, Naoki, Jahit, Mohammad Shukri , Jáquez, Anayanet , Muscaritoli, Maurizio , Ng, Doris Hui Lan , Nyulasi, Ibolya , Pirlich, Matthias , Siltharm, S., Yu, Jianchun , Gossum, A. Van , Winkler, Marion F. , Compher, Charlene , Barazzoni, Rocco , Gautier, Juan B Ochoa , Gonzalez, M Cristina , Blaauw, Renee , Braz, Diana Cardenas , Carrasco, Fernando , Evans, David C , Fuchs-Tarlovsky, Vanessa , Gramlich, Leah , Hasse, Jeanette M , Hiesmayr, Michael , Jager-Wittenaar, Harriët , Jahit, Shukri , Jáquez, Anayanet , Keller, Heather , Malone, Ainsley , Mogensen, Kris M , Mundi, Manpreet S , Muscaritoli, Maurizio , Ng, Doris , Nyulasi, Ibolya , Schneider, Stephane , de van der Schueren, Marian , Singer, Pierre , Tappenden, Kelly A , Yu, Jianchun , Wang, Jaw-Yuan , Winkler, Marion F , Compher, Charlene , Gramlich, Leah , Shi, Han Ping , Kłęk, Stanisław , Malone, Ainsley , Mogensen, Kris M. , Mori, Naoharu , Mundi, Manpreet S. , Steiber, Alison

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | April 14, 2025 | Volume: 49 | Issue: 4 | Pages: 414-427

10.1002/jpen.2756 | PMID 40223699 Get It

Abstract Background The Global Leadership Initiative on Malnutrition (GLIM) introduced an approach for malnutrition diagnosis in 2019 that comprised screening followed by assessment of three phenotypic criteria (weight loss, low body mass index [BMI], and low muscle mass) and two etiologic criteria (reduced food intake/assimilation and inflammation/disease burden). This planned update reconsiders the GLIM framework based on published knowledge and experience over the past 5 years. Methods A working group ( n = 43 members) conducted a literature search spanning 2019–2024 using the keywords “Global Leadership Initiative on Malnutrition or GLIM.” Prior GLIM guidance activities for using the criteria on muscle mass and inflammation were reviewed. Successive rounds of revision and review were used to achieve consensus. Results More than 400 scientific reports were published in peer‐reviewed journals, forming the basis of 10 systematic reviews, some including meta‐analyses of GLIM validity that indicate strong construct and predictive validity. Limitations and future priorities are discussed. Working group findings suggest that assessment of low muscle mass should be guided by experience and available technological resources. Clinical judgment may suffice to evaluate the inflammation/disease burden etiologic criterion. No revisions of the weight loss, low BMI, or reduced food intake/assimilation criteria are suggested. After two rounds of review and revision, the working group secured 100% agreement with the conclusions reported in the 5‐year update. Conclusion Ongoing initiatives target priorities that include malnutrition risk screening procedures, GLIM adaptation to the intensive care setting, assessment in support of the reduced food intake/assimilation criterion, and determination of malnutrition in obesity.
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
Dima, Danai , Afrough, Aimaz , Goel, Utkarsh , Grajales‐Cruz, Ariel , Khouri, Jack , Julian, Kelley , Banerjee, Rahul , Razzo, Beatrice M. , Ferreri, Christopher J. , Martinez, Mariola Alejandra Vazquez, Davis, James A. , Sannareddy, Aishwarya , Raza, Shahzad , Portuguese, Andrew J. , Gaballa, Mahmoud , Rana, Masooma , DeJarnette, Shaun, Gonzalez, Rebecca , Mikkilineni, Lekha , Hosoya, Hitomi , Ouchveridze, Evguenia, Shune, Leyla , Lin, Yi , Sborov, Douglas W. , Anderson, Larry D. , Cowan, Andrew J., Patel, Krina K. , Voorhees, Peter M. , Sidana, Surbhi , Hansen, Doris K., Susanibar-Adaniya, Sandra P. , Grajales-Cruz, Ariel F , Banerjee, Rahul , Vazquez-Martinez, Mariola A , Davis, James A , Portuguese, Andrew J , Rana, Masooma S , Lieberman-Cribbin, Alex , Chen, Anna , Herr, Megan M. , Anwer, Faiz , Sborov, Douglas W , Garfall, Alfred L , Lee, Hans C , Anderson, Larry D , Patel, Krina , Voorhees, Peter , Sidana, Surbhi , Dima, Danai , Raza, Shahzad , Hosoya, Hitomi , Julian, Kelley L , Susanibar-Adaniya, Sandra P , Pasvolsky, Oren , Vazquez‐Martinez, Mariola , Puglianini, Omar Castañeda , Ouchveridze, Evguenia, Kaur, Gurbakhash , Rossi, Adriana , Anwer, Faiz , Richard, Shambavi , Baz, Rachid , Garfall, Alfred L. , Lee, Hans C. , Hansen, Doris K. , Atrash, Shebli

Mayo Clinic

Blood Advances | April 8, 2025 | Volume: 9 | Issue: 14 | Pages: 3408-3417

10.1182/bloodadvances.2025016059 | PMID 40198766 Get It

Abstract Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) &lt;40 mL/min. CrCl &lt;30 mL/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade ≥3: 1.2% vs 1%) and immune effector cell–associated neurotoxicity syndrome (16% vs 13%; grade ≥3: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade ≥3 anemia and grade ≥3 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI.
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Rankin, Alexander W. , Hoang, Chloe, Semchenkova, Alexandra , Myers, Regina M. , Wang, Hao‐Wei , Kovach, Alexandra E. , Yuan, Constance M. , Colon, Dana Delgado, Vasseur, Loïc , John, Samuel , Lyons, Kaylyn Utley , Friedes, Barbara D., Alonso‐Saladrigues, Anna , Abdel‐Azim, Hisham , Balducci, Estelle , Aljudi, Ahmed Assim , Balsat, Marie , Biery, D. N. , Chamdin, Aghiad, Cuevo, Raymund S., Dickens, David S. , Duffner, Ulrich, Elliott, Michelle A. , Escherich, Gabriele , Fernandes, Sneha, Fitzjohn, Mandi R., Gahvari, Zhubin, He, Rui , Harrison, Cynthia , Hergott, Christopher A. , Hsieh, Emily M. , Larson, Daniel P. , Lee, Benjamin J. , Leguay, Thibaut , Mangaonkar, Abhishek A. , Mezger, Kerstin, Pacenta, Holly , Provost, Marlie R. M., Puri, Latika, Raikar, Sunil S. , Martinez, Armando, Bristol, Isabella Quijada, Murphy, Kyle, Reiman, Lauren T. , Redell, Michele S. , Reed, Kelly, Guépin, Gabrielle Roth, Savaşan, Süreyya , Schafernak, Kristian T. , Stevens, Alexandra M. , Talleur, Aimee C. , Carapia, Naomi Torres, Vargaftig, Jacques , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Sasaki, Koji , Davis, Kara L. , Ghorashian, Sara , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Rankin, Alexander W , Semchenkova, Alexandra , Myers, Regina M , Zerkalenkova, Elena , Wang, Hao-Wei , Kovach, Alexandra E , Yuan, Constance M , Vasseur, Loïc , Alonso-Saladrigues, Anna , Balducci, Estelle , Aljudi, Ahmed Assim , Chang, Bill H , Cuevo, Raymund S , De Moerloose, Barbara , Dickens, David S , Duployez, Nicolas , Elliott, Michelle Ann, Harrison, Cynthia , Kim, Annette S , Kuo, Dennis J , Larson, Daniel P , Lee, Benjamin J , Leguay, Thibaut , Lindsley, R Coleman , Puri, Latika , Raikar, Sunil S , Rubinstein, Jeremy , Schafernak, Kristian , Talleur, Aimee , Vatsayan, Anant , Wölfl, Matthias , Rives, Susana , Fabrizio, Vanessa A , Sasaki, Koji , Boissel, Nicolas , Rheingold, Susan R , Davis, Kara L , Ghorashian, Sara , Popov, Alexander , Shah, Nirali N , Silbert, Sara K. , Zerkalenkova, Elena , Colon, Dana Delgado, Bataller, Alex , Biery, D. Nathan, Chaer, Firas El , Grupp, Stephan A. , Pan, Jing , Martinez, Armando, Murphy, Kyle, Zhao, Liping, Aldoss, Ibrahim

Mayo Clinic

Blood | April 7, 2025 | Volume: 146 | Issue: 4 | Pages: 437-455

10.1182/blood.2024026655 | PMID 40193715 Get It

Abstract Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as “lineage drift” were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of &lt;40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Banerjee, Rahul , Richards, Alicia, Midha, Shonali , Afrough, Aimaz , Anwer, Faiz , Atanackovic, Djordje , Bachanová, Veronika , Bhurtel, Jenny , Cicero, Kara I. , Davis, James A. , Dhakal, Binod , Ferreri, Christopher J. , Forsberg, Peter A. , Freeman, Ciara L. , Khouri, Jack , Kumar, Anupama, Liu, Yuxin , Mikkilineni, Lekha , Peres, Lauren C. , Purvey, Sneha , Raza, Shahzad , Sborov, Douglas W. , Shune, Leyla , Wagner, Charlotte B , Zanwar, Saurabh , Sidana, Surbhi , Patel, Krina K. , Kumar, Shaji , Lin, Yi , Martin, Thomas G. , Voorhees, Peter M. , Anderson, Larry D. , Cowan, Andrew J., Chhabra, Saurabh , Davis, James A , Dhakal, Binod , Freeman, Ciara L , Herr, Megan M. , Jain, Tania , Khouri, Jack , Kocoglu, Mehmet H , McGuirk, Joseph , Parrondo, Ricardo D , Pasvolsky, Oren , Sborov, Douglas W , Wagner, Charlotte , Zanwar, Saurabh S , Sidana, Surbhi , Patel, Krina , Kumar, Shaji K , Voorhees, Peter , Anderson, Larry D , Kaur, Gurbakhash , Bachanova, Veronika , Banerjee, Rahul , Raza, Shahzad , Anwer, Faiz , Atrash, Shebli , Beitinjaneh, Amer , Puglianini, Omar Castañeda , Chhabra, Saurabh , Dima, Danai , Jain, Tania , Janakiram, Murali , Kocoglu, Mehmet H. , Locke, Frederick L. , McGuirk, Joseph P. , Nadeem, Omar , Pasvolsky, Oren , Reshef, Ran , Richard, Shambavi , Rossi, Adriana , Hansen, Doris K. , Kaur, Gurbakhash

Mayo Clinic

Blood Advances | March 15, 2025 | Volume: 9 | Issue: 9 | Pages: 2336-2340

10.1182/bloodadvances.2025016131 | PMID 40088469 Get It

Determinants of late metastases in renal cell carcinoma
Kapur, Payal , Zhong, Hua , Christie, Alana , Xu, Haitao , Cai, Qi , Araj, Ellen, Kim, David , Miyata, Jeffrey , Tcheuyap, Vanina Toffessi , Ball, Colleen T. , Thiel, David D. , Parker, Alexander S. , Antwi, Samuel O. , Leibovich, Bradley C. , Cheville, John C. , Tcheuyap, Vanina T , Leibovich, Bradley C , Modrusan, Zora , Brugarolas, James , Antwi, Samuel O , Kapur, Payal , Kim, David , Modrušan, Zora , Brugarolas, James

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 11, 2025 | Volume: 117 | Issue: 7 | Pages: 1387-1400

10.1093/jnci/djaf060 | PMID 40065697 Get It

Abstract Background The mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. Methods This study evaluated 2 large independent cohorts for differences in tumor biology between patients who developed metastases early (≤1 year after nephrectomy) and those with late onset (&gt;3 years). Results In the discovery cohort (n = 161), late metastatic RCC was associated with clear cell histology (88.9% vs 78.7%), lower pathological stage (pT1-2; 40.3% vs 18.0%), and favorable histopathological features including low grade (40.0% vs 2.3%), less sarcomatoid (5.6% vs 21.8%), and reduced necrosis (37.7% vs 78.3%; all P &lt; .02). Late metastatic RCC tumors exhibited increased angiogenesis (63.5% vs 19.4%) and reduced inflammation (78.8% vs 50.0%; all P &lt; .02) profiles. Genomic driver analyses revealed comparable rates of PBRM1 and SETD2 loss in late and early metastatic RCC, while BAP1 loss was significantly less common in late metastatic RCC (7.5% vs 27.1%; P &lt; .02). In multivariable models, BAP1/PBRM1/SETD2 status and tumor necrosis emerged as key discriminators of late metastatic RCCs. These findings were confirmed in the second cohort (n = 307). Late metastatic RCC was enriched for fatty acid oxidation and angiogenesis pathways, supporting a less aggressive phenotype. This was further evidenced by a lower engraftment rate in murine models (0% vs 36.5%; P &lt; .001) and significantly longer overall survival from the time of metastasis (median survival doubled, P &lt; .001). Interestingly, late metastatic RCC shared genomic and phenotypic features with RCC that metastasizes to the pancreas, suggesting a common underlying biology influencing both metastatic latency and pancreatic tropism. Conclusions Overall, these findings advocate for recognition of late metastatic RCC because of its distinct biology and improved prognosis.